Efficacy and safety of domestic dasatinib as second-line treatment for chronic myeloid leukemia patients in the chronic phase

Objective To investigate the efficiency and safety of domestic tyrosine kinase inhibitor(TKI)dasatinib(Yinishu)as second-line treatment for patients with chronic myeloid leukemia in chronic phase(CML-CP).Methods A retrospective analysis of clinical data of CML-CP patients who received domestic dasatinib as second-line treatment in the CML collaborative group hospitals of Hubei province from March 2016 to July 2018 was performed.The optimal response rate,the cumulative complete cytogenetic response(CCyR),the cumulative major molecular responses(MMR),progression free survival(PFS),event free survival(EFS)and adverse effects(AEs)of the patients were assessed at 3,6 and 12 months of treatment.Results A total of 83 CML-CP patients were enrolled in this study.The median followup time was 23 months.The optimal response rates at 3,6 and 12 months in 83 CML-CP patients treated with dasatinib were 77.5%(54/71),72.6%(61/75)and 60.7%(51/69),respectively.By the end of followup,the cumulative CCyR and MMR rates were 65.5%(55/80)and 57.1%(48/73),respectively.The median time to achieve CCyR and MMR was 3 months.During follow-up time,the PFS rate was 94.0%(79/83)and the EFS rate was 77.4%(65/83).The most common non-hematological AEs of dasatinib were edema(32.5%),rash itching(18.1%)and fatigue(13.3%).The common hematological AEs of dasatinib were thrombocytopenia(31.3%),leukopenia(19.3%)and anemia(6.0%).Conclusion Domestic dasatinib was effective and safe as the second-line treatment of CML-CP patients and it can be used as an option for CML-CP patients.